We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.
- Authors
Merino, Delphine; Whittle, James R.; Vaillant, François; Serrano, Antonin; Jia-Nan Gong; Giner, Goknur; Maragno, Ana Leticia; Chanrion, Maïa; Schneider, Emilie; Bhupinder Pal; Xiang Li; Dewson, Grant; Gräsel, Julius; Liu, Kevin; Lalaoui, Najoua; Segal, David; Herold, Marco J.; Huang, David C. S.; Smyth, Gordon K.; Geneste, Olivier
- Abstract
The article discusses the development of BH3 mimetics in the breakthrough of cancer therapy which antagonize prosurvival proteins of the BCL-2 family. It examines the synergistic activity of docetaxel in breast cancer andwith trastuzumab or lapatinib. It also cites the regulation of prosurvival proteins in the resistance of breast cancer.
- Subjects
BREAST cancer diagnosis; CANCER treatment; PROTEINS; DOCETAXEL; SURVIVAL behavior (Humans)
- Publication
Science Translational Medicine, 2017, Vol 9, Issue 401, p1
- ISSN
1946-6234
- Publication type
Article
- DOI
10.1126/scitranslmed.aam7049